The pharmacological mechanism of Chinese herbs effective in treating advanced ovarian cancer: Integrated meta-analysis and network pharmacology analysis

Ze Yang1,2†, Xiang Wang2†, Wei Hong1†, Shiyi Zhang3, Yang Yang3, Yongliang Xia4* and Ruiwen Yang4*

1The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China, 2Department of Orthopedics, Tongde Hospital of Zhejiang Province, Hangzhou, China, 3Department of Traditional Chinese Medicine, Neighborhood Good Doctor No. 6 Street Clinic, Hangzhou, China, 4Health Management Center, The First Afﬁliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China

Background: Advanced ovarian cancer (AOC) develops rapidly, adding to difﬁculties in treatment. Traditional Chinese medicine (TCM) plays a signiﬁcant role in the treatment of AOC, and so to explore the efﬁcacy and safety of TCM in the treatment of AOC and its effective targets, we performed the following review.

Methods: The major databases were searched for randomized controlled trials of TCM for the treatment of AOC. A meta-analysis of the efﬁcacy of Chinese herbs on AOC was conducted using RevMan 5.4 software. Active compounds and target genes were acquired using the TCMSP database. The main targets of AOC were obtained through the GenCards, OMIM, TTD, and DrugBank databases. A protein–protein interaction network carried out on the STRING platform was used to select core genes. The Metascape platform was applied to achieve GO and KEGG enrichment analysis.

Results: A total of 24 studies were included. Meta-analysis shows the TCM group improved the overall response rate (OR = 2.71; 95% CI = [2.14, 3.44], Z = 8.25, \( p < 0.00001 \)), overall survival (OR = 2.93, 95% CI = [2.03, 4.24], Z = 5.72, \( p < 0.00001 \)), and progression-free survival (OR = 5.36, 95% CI = [5.03, 5.69], Z = 31.88, \( p < 0.00001 \)) of AOC patients, as well as reducing many adverse events. There were 120 compounds, 246 herb target genes, and 1503 disease targets extracted. The 10 most important components were quercetin, kaempferol, 7-methoxy-2-methyl isoflavone, formononetin, isorhamnetin, hederagenin, stigmasterol, luteolin, 7-O-methylisomucronulatol, and calycosin. The 20 core targets were TP53, STAT3, JUN, AKT1, MAPK3, RELA, MAPK1, ESR1, IL6, FOS, MAPK14, TNF, CDKN1A, RB1, CCND1, EGF, STAT1, MDM2, MAPK8, and CAV1. KEGG enrichment analysis showed that there are many pathways directly related to different types of tumors, such as in pathway cancer and prostate cancer.
Conclusion: Our article reveals TCM is effective and safe against AOC and that Chinese herbs exert effects on the disease through multi-target, multi-component, and multi-pathway mechanisms.

Systematic Review Registration: (www.crd.york.ac.uk/PROSPERO/), identifier (CRD42022369731).

KEYWORDS
advanced ovarian cancer, traditional Chinese medicine, meta-analysis, network pharmacology analysis, review

Introduction

Ovarian cancer (OC) ranks fifth among cancer deaths in women, representing a larger number of deaths than any other cancer type of the female reproductive system, and is connected to the highest number of deaths among gynecological cancers in developed countries (Carioli et al., 2021; Craig et al., 2021).

Due to the complex anatomical structure and endocrine function of ovarian tissue, together with the lack of obvious clinical symptoms in the early stages (Han and Shen, 2015), the onset of OC is insidious (Menon et al., 2018). Most ovarian cancer cases are diagnosed at an advanced stage with a 5-year survival of just 15%–25% (Torre et al., 2018; Lheureux et al., 2019a). The main treatment for advanced ovarian cancer (AOC) is primary debulking surgery, combined with carboplatin and paclitaxel chemotherapy (Colombo et al., 2019). However, up to 80% of patients inevitably develop chemo-resistance and experience relapses, with a median progression-free survival of 12–18 months (Lheureux et al., 2019b). Moreover, many patients cannot tolerate the adverse reactions caused by long-term chemotherapy, which has a serious impact on their prognosis.

In recent years, considerable experience has been accumulated in the use of traditional Chinese medicine (TCM) in the treatment of OC, and with the characteristics of overall conditioning and multi-target intervention, TCM has achieved good results in assisting with chemotherapy (Xu et al., 2015; Wang et al., 2016; Yang, 2020). However, the clinical characteristics of effective herbs for AOC and their components and targets have not been explored before. Therefore, our article aims to evaluate effective herbs in the treatment of AOC through meta-analysis. Moreover, the potential pharmacological mechanism of such effective herbs is explored using a network pharmacology approach.

Materials and methods

Meta-analysis of the efficacy and safety of TCM for AOC

Database and search strategies

We searched PubMed, Embase, the Cochrane Library, the Chinese Biomedical Literature (CBM) database, the China Biomedical Literature database, and other relevant databases. We also manually searched references from included studies to identify additional relevant studies.

TABLE 1 Inclusion and exclusion criteria.

| PICOS         | Inclusion criteria                                                                 | Exclusion criteria                                                                 |
|---------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Participants  | 1 Age 18 years or older<br>2 Pathologically diagnosed as AOC, according to the FIGO system (Fédération Internationale de Gynécologie et d’Obstétrique), which considers the extent of tissue involvement, lymph node status, and the magnitude of metastasis. The stage III and stage IV cancers that spread beyond the pelvic cavity are called AOC (11)<br>3 Indications of chemotherapy, exclusion of contraindications of chemotherapy, lack of center, liver, kidney, and other major organs and serious systemic diseases<br>4 Estimated survival ≥ 3 months | 1 Younger than 18 years<br>2 Unclear diagnosis of AOC<br>3 Contraindications of chemotherapy, including lack of center, liver, kidney, and other major organs and serious systemic diseases<br>4 Estimated survival < 3 months |
| Intervention  | The intervention group was treated with TCM therapy including oral TCM decoction and Chinese patent medicine combined with chemotherapy. Chemotherapy regimens were not restricted | The intervention group was treated with acupuncture, tuina, or acupoint application and other external therapies of Chinese medicine |
| Comparison    | The control group was treated with conventional chemotherapy | The control group was treated with TCM treatment |
| Outcome       | Overall response rate (ORR), overall survival (OS), progression-free survival (PFS), and adverse events (AEs) | Incomplete or unidentified data |
| Study design  | Randomized controlled trial (RCT) | Non-RCTs |
| Others        | None | Duplicate publications, abstracts, reviews, case reports, and letters |
National Knowledge Infrastructure (CNKI) database, and the Wanfang database for updated articles published from the establishment of each database to 1 August 2022. The search keywords we used included: (“randomized controlled trials as topic” OR “controlled clinical trial” OR “randomized” OR “placebo” OR “clinical trial” OR “controlled trial”) AND (“decoction” OR “formula” OR “Tang” OR “Traditional Chinese medicine”) AND (“neoplasm metastasis” OR “IV stage” OR “advanced ovarian cancer” OR “metastatic ovarian cancer” OR “ovarian cancer” OR “ovarian neoplasms”).

Eligibility criteria
Detailed inclusion and exclusion criteria are shown in Table 1.

Study selection and data extraction
Two researchers (ZY and XW) independently searched the articles in the databases. The titles and abstracts were screened according to the inclusion and exclusion criteria, and then the full texts of the remaining articles were screened for a final decision. If there was a disagreement, the third researcher (RWY) would be consulted. The extraction information from the included studies entailed: first author, sample size, mean age or age range, clinical status, common treatment (regimen), TCM interventions, control interventions, duration time, and main outcomes.

Assessment of the risk of bias
The risk of bias for all included studies was assessed by two researchers (ZY and XW) independently, based on the Cochrane...
risk bias tool in the Cochrane Handbook for Systematic Reviews of Interventions (Cumpston et al., 2019). The risk bias includes random sequence generation, allocation concealment, blinding of participants and implementers, blinding of outcome assessment, incomplete outcome data, selective reporting, and other potential biases.

### TABLE 2 Characteristics of the 24 studies included in the meta-analysis.

| Study | Sample size (T/C) | Mean age or age range | Clinical status | Common treatment (regimen) | TCM intervention | Control intervention | Main outcome |
|-------|-------------------|------------------------|----------------|-----------------------------|-----------------|---------------------|--------------|
| Chen2012 | 27/25 | 52.36 ± 6.48 | KPS > 60 | TP | TCM experience formula | No additional Tx | ③ |
| Chen2017 | 50/50 | 66.32 ± 6.01 | KPS ≥ 60 | Carboplatin | TCM | No additional Tx | ②③ |
| Chen2014 | 43/34 | 48.8 ± 4.1 | Not mentioned | Taxol | Fuzheng Xiaoliu decoction | No additional Tx | ③ |
| Dai2021 | 35/35 | 52.15 ± 6.83 | KPS > 60 | TC | Guizhi Fuling Wan | No additional Tx | ③ |
| Fang2019 | 56/56 | 51.52 ± 7.38 | KPS ≥ 60 | TC | Wenyang Yiqi Jianpi decoction | No additional Tx | ②③ |
| Hou2018 | 38/32 | 52.27 ± 7.50 | Not mentioned | TP | TCM | No additional Tx | ③ |
| Hu2019 | 40/40 | 58.41 ± 3.70 | KPS ≥ 60 | TC | Jiandu Yiasi decoction | No additional Tx | ③ |
| Huang2022 | 40/40 | 52.12 ± 7.65 | KPS ≥ 60 | TC | Wenyang Yiqi Jianpi decoction | No additional Tx | ③ |
| Jia2017 | 42/42 | 53.55 ± 4.51 | 39.7 ± 15.4 | TP | TCM | No additional Tx | ③ |
| Jin2015 | 43/34 | 51.5 ± 4.3 | 50.7 ± 3.6 | Taxol | Fuzheng Xiaoliu decoction | No additional Tx | ③ |
| Li2020 | 153/146 | 54 ± 9 | 56 ± 9 | KPS ≥ 70 | Paclitaxel and platinum-based chemotherapy | Wenyang Yiqi Huoxue Jiayao decoction | Placebo | ③ |
| Li2021 | 54/54 | 60.12 ± 6.78 | KPS ≥ 60 | TC | Wenyang Yiqi Huoxue Jiayao decoction | No additional Tx | ③ |
| Liang2013 | 60/60 | 24.72 | 22.73 | KPS ≥ 60 | TP | Zengmian Yili decoction | No additional Tx | ③ |
| Pan2018 | 28/28 | 62.13 ± 3.67 | 61.79 ± 3.50 | Not mentioned | Docetaxel + cisplatin | Wenyang Yiqi Jianpi decoction | No additional Tx | ③ |
| Pei2011 | 35/35 | 52.23 ± 3.46 | 51.77 ± 2.81 | KPS ≥ 70 | Basic chemotherapy | Lichong decoction | No additional Tx | ③ |
| Ren2019 | 44/44 | 51.09 ± 8.32 | 50.19 ± 6.77 | Not mentioned | TP | Fuzheng Quji decoction | No additional Tx | ③ |
| Wang2022 | 46/46 | 49 | 52 | KPS > 60 | Basic chemotherapy + docetaxel | Wenyang Yiqi decoction | No additional Tx | ③ |
| Yang2017 | 23/23 | 50.31 ± 10.36 | 51.31 ± 9.74 | Not mentioned | Basic chemotherapy | Wenyang Yiqi decoction | No additional Tx | ③ |
| Yang2021 | 56/42 | 52.23 ± 8.97 | 51.64 ± 8.56 | Not mentioned | TC | Compound Daqiqi Decoction | No additional Tx | ③ |
| Zhang2018 | 46/46 | 52.03 ± 9.12 | 51.80 ± 9.24 | Not mentioned | TP | TCM | No additional Tx | ③ |
| Zhang2016 | 36/36 | 59.47 ± 9.03 | 58.94 ± 8.63 | KPS > 30 | TP | TCM | No additional Tx | ③ |
| Zhao2016 | 24/24 | 55 | Not mentioned | TC | Taohong Siwu decoction | No additional Tx | ③ |
| Zhou2017 | 30/30 | 55.13 ± 2.53 | 54.68 ± 2.58 | Not mentioned | TP | Jianpi Jiedu Sanjie decoction | No additional Tx | ③ |
| Zhou2020 | 48/48 | 54.78 ± 5.48 | 55.13 ± 5.51 | KPS > 60 | TP | Lichong decoction | No additional Tx | ③ |
Statistical analysis

RevMan 5.4 software was employed for analyzing the collected data. The odds ratio (OR) was used as the effect size index for the dichotomous variables, and the mean difference (MD) was used as the effect size index for the continuous variables, with 95% confidence intervals (CI) in forest plots. If heterogeneity existed ($p < 0.1$ or $I^2 > 50\%$) between the two groups, the random-effects model was adopted. Otherwise, the fixed-effects model was used. Subgroup analyses were performed based on the types of OS and AEs. Publication bias was evaluated visually using funnel plots in RevMan 5.4 software.

Network pharmacology of effective herbs for AOC

Analysis of the frequency of the presence of herbs in prescriptions extracted from articles was included in the above meta-analysis. Herbs with a frequency greater than 50% were considered effective herbs and were used for subsequent network pharmacology analysis.

Screening of active compounds and target genes of effective herbs and the herb–component–target network

The chemical compounds of effective herbs were obtained through the TCMSP database (http://tcmsp.com/tcmsp.php). Active compounds of herbs were selected if their drug-likeness (DL) index $\geq 0.18$ and oral bioavailability (OB) $\geq 30\%$. Then, using the UniProt database (https://www.uniprot.org) to annotate the related target genes, the herb–component–target network of herbs effective against AOC was established by Cytoscape3.7.2 software, with the 10 most important components selected according to their degree value in the network.

Screening of disease targets

High correlation AOC-related targets were extracted by searching the keyword term “advanced ovarian cancer” from the following public databases: DrugBank (https://www.drugbank.ca/), GeneCards (https://www.genecards.org/), OMIM (http://omim.org/), and TTD (http://db.idrblab.net/ttd/).

Acquisition of intersectional genes and construction of protein–protein interaction

Genes intersecting the target genes of effective herbs and the targets of AOC were extracted using a Venn diagram made on a website (https://bioinfogp.cnb.csic.es/tools/venny/index.html). The intersectional genes were then imported into the STRING platform (https://stringdb.org/). Homo was the species, a score $> 0.9$ was set, and the independent target protein nodes were hidden. The results were exported in TSV format and then imported into Cytoscape3.7.2. The CytoNCA plugin calculated the following four parameters: betweenness centrality (BC), closeness centrality (CC), degree centrality (DC), and eigenvector centrality (EC), and the first 20 core genes with higher than average values were extracted.

GO and KEGG enrichment analysis

The KEGG pathway enrichment analysis and GO enrichment analysis were obtained based on the Metascape database (https://metascape.org/gp/index.html). The GO enrichment analysis included the biological process (BP), molecular function (MF), and cellular component (CC) analysis. The top 10 records with q value $< 0.05$ in terms of GO enrichment analysis and the top 20 KEGG pathways were extracted, with the latter imported into Cytoscape3.7.2 for visualization of the target–pathway network of effective prescription herbs against AOC.
Results

Results of meta-analysis

Search results

All 525 records were obtained by searching the databases, of which 118 records were excluded for duplication. After screening titles and abstracts, a further 347 items were removed because they were conference abstracts, basic research, clinical research, reviews, or irrelevant. Sixty articles were reviewed for full-text evaluation, among which 36 were excluded for having low quality, irrelevant outcomes, inappropriate inventions, non-RCTs, or not being related to AOC. Finally, 24 were included in this meta-analysis (Pei, 2010; Chen, 2012; Liang, 2013; Chen et al., 2014; Jin and Kong, 2015; Zhang, 2016; Zhao et al., 2016; Chen and Hua, 2017; Jia, 2017; Yang, 2017; Zhou, 2017; Hou and Wu, 2018; Pan, 2018; Zhang et al., 2018; Fang et al., 2019; Hu, 2019; Ren and Feng, 2019; Li et al., 2020; Zhou et al., 2020; Dai and Liu, 2021; Li et al., 2021; Yang and Mi, 2021; Huang et al., 2022; Wang et al., 2022). No further study was identified by manual search. The flow diagram of studies selection is shown in Figure 1, while the main characteristics of the 24 included articles are provided in Table 2.

Assessment of risk of bias

The results of the assessment of risk of bias are shown in Figures 2, 3. All articles employed randomization, and 15 studies using the means of random number table were considered to have a low risk of bias. Those studies that did not mention specific random methods were considered to possess an unclear risk of bias. One study (Li et al., 2020) which mentioned allocation concealment, blinding of participation, and outcome assessment, was considered low risk; others did not mention whether allocation concealment and blinding of participation was adopted or not, and were thus considered to have an unclear risk of bias. All studies were completed with data and considered low risk. Selective reporting and other biases in the included articles resulted in an unclear risk of bias, since these potential biases were not acknowledged in the articles.

Overall response rate

Data from 17 related studies indicating overall response rate were synthesized. In AOC patients, the ORR in the TCM combined with the chemotherapy group was significantly better than in the other group (OR = 2.71; 95% CI = [2.14, 3.44], Z = 8.25, p < 0.00001) (Figure 4).

Overall survival

As shown in Figure 5, seven related studies employed a fixed-effects model for the pool of data reflecting overall survival (OS).
FIGURE 4
Forest plots for comparison of ORR between TCM group and control group.

FIGURE 5
Forest plots and subgroup analysis for comparison of OS between TCM group and control group.
FIGURE 6
Forest plots and subgroup analysis for comparison of PFS between TCM group and control group.

FIGURE 7
Forest plots and subgroup analysis for gastrointestinal adverse event.
### 3.1 Myelosuppression

| Study or Subgroup | Experimental Events | Control Events | Experimental Total | Control Total | Weight | M.H. Fixed, 95% CI | Odds Ratio M.H. Fixed, 95% CI |
|-------------------|---------------------|----------------|-------------------|---------------|--------|-------------------|-----------------------------|
| Chen2017          | 0                   | 23             | 1                 | 23            | 0.5%   | 0.32 [0.01, 8.25] |                             |
| Fang2019          | 14                  | 46             | 12                | 46            | 2.9%   | 1.24 [0.50, 3.08] |                             |
| Huang2022         | 14                  | 40             | 24                | 40            | 5.4%   | 0.36 [0.14, 0.89] |                             |
| Wang2022          | 20                  | 56             | 34                | 56            | 7.6%   | 0.36 [0.17, 0.77] |                             |
| Yang2017          | 32                  | 50             | 34                | 50            | 4.3%   | 0.84 [0.37, 1.92] |                             |
|                  | Total               | 194            | 474               | 215           | 20.7%  | 0.59 [0.38, 0.88] |                             |

Total events: 80

Heterogeneity: Chi² = 6.13, df = 4 (P = 0.35); I² = 35%

Test for overall effect: Z = 2.59 (P = 0.010)

### 3.2 Leukopenia

| Study or Subgroup | Experimental Events | Control Events | Experimental Total | Control Total | Weight | M.H. Fixed, 95% CI | Odds Ratio M.H. Fixed, 95% CI |
|-------------------|---------------------|----------------|-------------------|---------------|--------|-------------------|-----------------------------|
| Chen2014          | 2                   | 43             | 4                 | 34            | 1.5%   | 0.37 [0.06, 2.13] |                             |
| Dai2021           | 5                   | 35             | 13                | 35            | 3.9%   | 0.28 [0.09, 0.91] |                             |
| Hu2019            | 6                   | 40             | 13                | 40            | 3.8%   | 0.37 [0.12, 1.09] |                             |
| Jin2015           | 2                   | 43             | 4                 | 34            | 1.5%   | 0.37 [0.08, 2.13] |                             |
| Li2021            | 7                   | 54             | 6                 | 54            | 1.8%   | 0.19 [0.03, 1.0]  |                             |
| Liang2013         | 14                  | 60             | 6                 | 60            | 1.6%   | 0.74 [0.52, 1]    |                             |
| Ren2019           | 14                  | 44             | 24                | 44            | 6.6%   | 0.27 [0.11, 0.64] |                             |
| Zhang2016         | 14                  | 36             | 23                | 36            | 4.9%   | 0.36 [0.14, 0.93] |                             |
| Zhou2017          | 1                   | 30             | 3                 | 30            | 1.0%   | 0.31 [0.03, 3.17] |                             |
| Zhou2020          | 3                   | 48             | 13                | 48            | 4.2%   | 0.19 [0.05, 0.68] |                             |
|                  | Total               | 433            | 415               | 390           | 30.9%  | 0.48 [0.33, 0.68] |                             |

Total events: 68

Heterogeneity: Chi² = 18.74, df = 9 (P = 0.03); I² = 52%

Test for overall effect: Z = 4.06 (P < 0.0001)

### 3.3 Anemia

| Study or Subgroup | Experimental Events | Control Events | Experimental Total | Control Total | Weight | M.H. Fixed, 95% CI | Odds Ratio M.H. Fixed, 95% CI |
|-------------------|---------------------|----------------|-------------------|---------------|--------|-------------------|-----------------------------|
| Chen2014          | 4                   | 43             | 5                 | 34            | 1.8%   | 0.59 [0.15, 2.41] |                             |
| Dai2021           | 4                   | 35             | 11                | 35            | 3.4%   | 0.28 [0.08, 0.99] |                             |
| Hu2019            | 7                   | 40             | 14                | 40            | 4.0%   | 0.39 [0.14, 1.12] |                             |
| Jin2015           | 4                   | 43             | 5                 | 34            | 1.8%   | 0.59 [0.15, 2.41] |                             |
| Li2021            | 4                   | 54             | 3                 | 54            | 1.0%   | 1.36 [0.29, 6.39] |                             |
| Liang2013         | 4                   | 60             | 12                | 60            | 3.9%   | 0.29 [0.09, 0.94] |                             |
| Ren2019           | 6                   | 44             | 17                | 44            | 5.1%   | 0.25 [0.09, 0.72] |                             |
| Zhang2016         | 9                   | 36             | 18                | 36            | 4.7%   | 0.33 [0.12, 0.9]  |                             |
| Zhou2017          | 1                   | 48             | 3                 | 48            | 1.0%   | 0.32 [0.03, 3.18] |                             |
| Zhou2020          | 3                   | 48             | 4                 | 48            | 1.3%   | 0.48 [0.08, 2.74] |                             |
|                  | Total               | 403            | 385               | 400           | 26.7%  | 0.39 [0.26, 0.56] |                             |

Total events: 43

Heterogeneity: Chi² = 4.52, df = 9 (P = 0.81); I² = 0%

Test for overall effect: Z = 4.58 (P < 0.00001)

### 3.4 Thrombocytopenia

| Study or Subgroup | Experimental Events | Control Events | Experimental Total | Control Total | Weight | M.H. Fixed, 95% CI | Odds Ratio M.H. Fixed, 95% CI |
|-------------------|---------------------|----------------|-------------------|---------------|--------|-------------------|-----------------------------|
| Dai2021           | 5                   | 35             | 13                | 35            | 3.9%   | 0.28 [0.09, 0.91] |                             |
| Hu2019            | 5                   | 40             | 11                | 40            | 3.4%   | 0.38 [0.12, 1.21] |                             |
| Li2021            | 5                   | 54             | 4                 | 54            | 1.3%   | 1.28 [0.32, 5.03] |                             |
| Ren2019           | 10                  | 44             | 21                | 44            | 5.7%   | 0.32 [0.13, 0.81] |                             |
| Zhang2016         | 12                  | 36             | 21                | 36            | 4.9%   | 0.36 [0.14, 0.93] |                             |
| Zhou2017          | 1                   | 30             | 4                 | 30            | 1.3%   | 0.22 [0.02, 2.14] |                             |
| Zhou2020          | 2                   | 48             | 4                 | 48            | 1.3%   | 0.48 [0.08, 2.74] |                             |
|                  | Total               | 287            | 287               | 217           | 21.7%  | 0.39 [0.25, 0.61] |                             |

Total events: 40

Heterogeneity: Chi² = 3.64, df = 6 (P = 0.72); I² = 0%

Test for overall effect: Z = 4.10 (P < 0.0001)

### Total (95% CI)

| Total Events | 1338 | 1302 | 100.0% | 0.45 [0.37, 0.56] |
|--------------|------|------|--------|-------------------|

Total events: 231

Heterogeneity: Chi² = 35.34, df = 30 (P = 0.23); I² = 15%

Test for overall effect: Z = 7.68 (P < 0.00001)

Test for subgroups: Chi² = 2.50, df = 3 (P = 0.48). I² = 0%

FIGURE 8
Forest plots and subgroup analysis for myelosuppression event.
The pooled results show that TCM combined with chemotherapy is beneficial in improving OS (OR = 2.93, 95% CI = [2.03, 4.24], Z = 5.72, p < 0.00001).

There were significant differences in 3-year survival between the TCM group and the control group in the subgroup analysis (OR = 3.10, 95% CI = [2.10, 4.59], Z = 5.66, p < 0.00001). However, there were no significant differences in 5-year survival (OR = 1.88, 95% CI = [0.62, 5.65], Z = 1.12, p < 0.00001).

**Progression-free survival**

Only one study reported the outcome of progression-free survival (PFS). This result indicated that the PFS in the TCM group was significantly higher than in the control group (OR = 5.36, 95% CI = [5.03, 5.69], Z = 31.88, p < 0.00001) (Figure 6).

**Adverse events**

Concerning adverse events, 17 of the included articles reported these. The most common type of adverse event reported was a gastrointestinal reaction. There were 16 studies reporting this, in which 5 reported gastrointestinal reactions generally, while others reported specific reactions, such as nausea, diarrhea, and constipation. The pooled results of 12 studies showed that the incidence of nausea in the TCM group was lower than in the WM group (OR = 0.47, 95% CI = [0.34, 0.68], Z = 4.69, p < 0.00001). Three studies reported the occurrence of diarrhea in the two groups, while the TCM group also did better in reducing the incidence of nausea (OR = 0.36, 95% CI = [0.15, 0.83], Z = 2.40, p = 0.02). Only two studies mentioned constipation, and in the TCM group, the incidence of constipation was significantly lower (OR = 0.31, 95% CI = [0.12, 0.76], Z = 2.55, p = 0.01). The results showing gastrointestinal reaction are in Figure 7.

The adverse event of myelosuppression was mentioned in 15 studies, 5 of them reporting myelosuppression generally, with the remainder reporting an instance of specific myelosuppression, such as leukopenia, anemia, or thrombocytopenia, as shown in Figure 8. TCM intervention can reduce the occurrence of myelosuppression (OR = 0.45, 95% CI = [0.37, 0.56], Z = 7.68, p < 0.00001). Ten trials reported the adverse event of leukopenia between the two groups, and the results showed that the TCM group did better in decreasing the incidence of leukopenia (OR = 0.48, 95% CI = [0.33, 0.68], Z =
In addition, 9 studies reported the occurrence of anemia. The pooled results showed that there were significant differences in the occurrence of anemia between the two groups (OR = 0.38, 95% CI = [0.26,0.58], Z = 4.58, p < 0.00001). Subgroup analysis of seven studies showed that TCM intervention can reduce the incidence of thrombocytopenia (OR = 0.39, 95% CI = [0.25,0.61], Z = 4.10, p < 0.0001).

Liver and kidney injury were also common when treating AOC. Liver injury in 11 trials and kidney injury in 2 studies were reported. Subgroup analysis showed both liver injury (OR = 0.57, 95% CI = [0.40,0.81], Z = 3.13, p = 0.002) and kidney injury (OR = 0.50, 95% CI = [0.36,0.70], Z = 3.05, p = 0.002) were reduced in the TCM group (Figure 9).

Some other adverse events were also mentioned. Among them, compared with the control group, the TCM group had benefit in reducing hematuria (OR = 0.14, 95% CI = [0.05,0.45], Z = 3.32, p = 0.0009), but no obvious effect on decreasing the incidence of muscle and joint pain (OR = 0.46, 95% CI = [0.21,1.01], Z = 1.93, p = 0.05), fatigue (OR = 0.31, 95% CI = [0.03,3.16], Z = 0.99, p = 0.32), neurotoxicity (OR = 0.66, 95% CI = [0.40,1.09], Z = 1.62, p = 0.10), but a significant reduction in muscle pain (OR = 0.38, 95% CI = [0.22,0.66], Z = 3.81, p = 0.0001).

| Study or Subgroup | TCM | Control | Odds Ratio | M.H. Fixed, 95% CI |
|-------------------|-----|---------|------------|-------------------|
| **3.4.1 Muscle and joint pain** | | | | |
| Dai2013 | 5 | 39 | 35 | 7.4% | 0.48 [0.14,1.62] |
| Hu2016 | 7 | 40 | 13 | 40 | 10.4% | 0.44 [0.15,1.28] |
| Subtotal (95% CI) | 75 | 75 | 17.8% | 0.46 [0.21,1.01] |
| Total events | 12 | 22 | | |
| Heterogeneity: Chi² = 0.01, df = 1 (p = 0.91); I² = 0% |
| Test for overall effect: Z = 1.93 (p = 0.05) |
| **3.4.2 Fatigue** | | | | |
| Pan2019 | 1 | 28 | 3 | 28 | 2.8% | 0.31 [0.03,3.18] |
| Subtotal (95% CI) | 28 | 28 | 2.8% | 0.31 [0.03,3.16] |
| Total events | 1 | 3 | | |
| Heterogeneity: Not applicable |
| Test for overall effect: Z = 0.99 (p = 0.32) |
| **3.4.3 Neurotoxicity** | | | | |
| Pan2017 | 1 | 28 | 2 | 28 | 1.9% | 0.48 [0.04,5.64] |
| Wang2022 | 15 | 46 | 14 | 46 | 9.1% | 1.11 [0.45,2.67] |
| Zhang2016 | 7 | 36 | 15 | 36 | 11.7% | 0.34 [0.12,0.97] |
| Subtotal (95% CI) | 69 | 69 | 11.2% | 0.66 [0.35,1.25] |
| Total events | 10 | 14 | | |
| Heterogeneity: Chi² = 2.92, df = 2 (p = 0.23); I² = 32% |
| Test for overall effect: Z = 1.26 (p = 0.20) |
| **3.4.4 Cardiotoxicity** | | | | |
| Wang2022 | 10 | 46 | 13 | 46 | 9.8% | 0.71 [0.07,1.62] |
| Yang2017 | 0 | 1 | 23 | 1.4% | 0.32 [0.01,1.26] |
| Subtotal (95% CI) | 69 | 69 | 11.2% | 0.66 [0.27,1.63] |
| Total events | 10 | 14 | | |
| Heterogeneity: Chi² = 0.21, df = 1 (p = 0.65); I² = 0% |
| Test for overall effect: Z = 0.91 (p = 0.36) |
| **3.4.5 Hematuria** | | | | |
| Liang2013 | 4 | 60 | 20 | 60 | 18.0% | 0.14 [0.05,0.45] |
| Subtotal (95% CI) | 60 | 60 | 18.0% | 0.14 [0.05,0.45] |
| Total events | 4 | 20 | | |
| Heterogeneity: Not applicable |
| Test for overall effect: Z = 3.32 (p = 0.0009) |
| **3.4.6 Hair loss** | | | | |
| Dai2013 | 2 | 35 | 3 | 35 | 27.8% | 0.65 [0.10,4.13] |
| Hu2018 | 7 | 40 | 9 | 40 | 7.2% | 0.73 [0.24,2.20] |
| Li2021 | 6 | 54 | 5 | 54 | 4.3% | 1.23 [0.35,4.28] |
| Pan2018 | 1 | 28 | 3 | 28 | 2.8% | 0.31 [0.03,3.18] |
| Ren2019 | 4 | 44 | 12 | 44 | 10.5% | 0.27 [0.00,0.91] |
| Subtotal (95% CI) | 201 | 201 | 27.5% | 0.58 [0.32,1.06] |
| Total events | 20 | 32 | | |
| Heterogeneity: Chi² = 3.38, df = 4 (p = 0.50); I² = 0% |
| Test for overall effect: Z = 1.76 (p = 0.07) |
| **3.4.7 Hypertension** | | | | |
| Total (95% CI) | 543 | 543 | 100.0% | 0.50 [0.36,0.69] |
| Total events | 70 | 122 | | |
| Heterogeneity: Chi² = 12.72, df = 13 (p = 0.47); I² = 0% |
| Test for overall effect: Z = 4.16 (p = 0.0001) |
| Test for subgroups: Chi² = 6.06, df = 5 (p = 0.30); I² = 17.5% |

FIGURE 10
Forest plots and subgroup analysis for other adverse events.
**Publication bias**

Funnel plots of ORR were adopted to assess publication bias. It was apparent from the funnel plot (Figure 11), that the result was nearly symmetrical, which indicates no significant publication bias existed.

**Results of network pharmacology analysis**

**Effective herbs extraction**

We analyzed the frequency of herbs appearing in the twenty different TCM formulas mentioned in the included articles. Sorted according to their frequency, the most effective herbs included: Baizhu, Huangqi, Fuling, Bai Hua She She Cao, Ezhu, Dangshen, and Gancao. The compounds of seven herbs were as follows: *Atractylodes macrocephala* Koidz. (Asteraceae; *Atractylodis macrocephalae* rhizoma); *Astragalus mongholicus* Bunge (Fabaceae; *Astragalii radix*); *Smilax glabra* Roxb. (Smilacaceae; *Rhzoma smilacis glabrae*); *Scleromitrion diffusum* (Wild.) R. J. Wang (Rubiaceae; *Oldenlandiae diffusae herba*); *Curcuma aromatica* Salisb. (Zingiberaceae; *Curcumae Longae Radix*); *Codonopsis pilosula* (Franch.) Nannf. (Campanulaceae; *Codonopsis pilosulae radix*); and *Glycyrrhiza glabra* L. (Fabaceae; *Extractum glycyrrhizae*), as shown in Table 3. A new effective formula was made up of these seven herbs for network pharmacology analysis.

**Establishment of herb–component–target network**

Through the search of the prescribed database, the seven effective herbs were found to be comprised of 120 compounds, and 246 herb target genes. Cytoscape3.7.2 software was adopted to establish the network of the compound and target genes of the effective herbs (Figure 12).

**Screening of intersectional genes of effective herbs, AOC, and the PPI network**

According to the four databases, AOC had 1503 disease targets: 121 target genes of herbs and disease intersected through the Venn diagram (Figure 13). The intersecting genes of the herb targets and the AOC targets were mapped into the STRING database, and the PPI network obtained. The network contained 121 nodes and 618 edges, with the average node degree being 10.2 ($p < 1.0e-16$) (Figure 14). The PPI network was introduced into Cytoscape, in which the CytoNCA plug-in was used and the first 20 genes were extracted as core genes (Figure 15).

**GO and KEGG enrichment analysis**

From the analysis of Supplementary Figure S1, the GO terms of the BP were mainly related to response to inorganic

---

**TABLE 3 High-frequency Chinese herbs.**

| Pharmaceutical name | Chinese name | Counts (counts/total herb counts) | Frequency 1 (counts/study numbers) | Frequency 2 (% Class of natural compound) |
|---------------------|-------------|---------------------------------|-----------------------------------|------------------------------------------|
| *Atractylodes macrocephala* Koidz | Baizhu | 19 | 7.22 | 79.17 | Asteraceae; *Atractylodis macrocephalae rhizoma* |
| *Astragalus mongholicus* Bunge | Huangqi | 17 | 6.46 | 70.83 | Fabaceae; *Astragalii radix* |
| *Smilax glabra* Roxb. | Fuling | 15 | 5.70 | 62.50 | Smilacaceae; *Rhzoma smilacis glabrae* |
| *Scleromitrion diffusum* (Wild.) R.J.Wang | Bai Hua She She Cao | 14 | 5.32 | 58.33 | Rubiaceae; *Oldenlandiae diffusae herba* |
| *Curcuma aromatica* Salisb. | Ezhu | 14 | 5.32 | 58.33 | Zingiberaceae; *Curcumae Longae Radix* |
| *Codonopsis pilosula* (Franch.) Nannf | Dangshen | 12 | 4.56 | 50.00 | Campanulaceae; *Codonopsis pilosulae radix* |
| *Glycyrrhiza glabra* L. | Gancao | 12 | 4.56 | 50.00 | Fabaceae; *Extractum glycyrrhizae* |
substances, response to reactive oxygen species, response to xenobiotic stimulus, response to oxidative stress, positive regulation of cellular component movement, positive regulation of cell migration, gland development, cellular response to chemical stress, positive regulation of cell motility, and response to hormones. The CC was mainly related to the transcription regulator complex, membrane raft, membrane microdomain, vesicle lumen, cyclin-dependent protein kinase holoenzyme complex, protein kinase complex, RNA polymerase II transcription regulator complex, secretory granule lumen, cytoplasmic vesicle lumen, and the serine/threonine protein kinase complex. In addition, the GO terms of the MF were mainly related to DNA-binding transcription factor binding, transcription factor binding, kinase binding, RNA polymerase II-specific DNA-binding transcription factor binding, protein kinase binding, protein kinase activity, phosphotransferase activity, alcohol group as acceptor, protein domain specific binding, kinase activity, and ubiquitin-like protein ligase binding.

The top 20 KEGG pathways are shown in Supplementary Figure S2. This verifies pathways in cancer (hsa05200), prostate cancer (hsa05215), bladder cancer (hsa05219), pancreatic cancer (hsa05212), the PI3K-Akt signaling pathway (hsa04151), proteoglycans in cancer (hsa05205), and hepatocellular carcinoma (hsa05225). The target–pathway network was constructed with the outer circle as the core gene and the inner circle as the related pathway according to the results of the KEGG enrichment analysis (Supplementary Figure S3).

**Discussion**

With changes in life pressure and dietary structure, the incidence of OC is increasing. Because of non-obvious early
symptoms, OC has the characteristic of a low early diagnosis rate, and more than 70% of patients are in advanced stages when diagnosed (Zhu et al., 2016). AOC develops rapidly, and tumor cells can spread to the uterus, omentum, and other parts in a short time, increasing the difficulty of treatment. Numerous studies have shown that Chinese herbs can effectively relieve the clinical symptoms of AOC patients and play an important role in the treatment of AOC. In a narrow sense, Chinese herbs refers to plant medicine. The medicinal part is divided into root and rhizome, stem and wood, bark, leaf, flower, fruit and seed, and whole herb, etc., and excludes animal medicine such as leech, and mineral medicine such as keel. However, in a broad sense, Chinese herbs can be understood as all non-proprietary Chinese medicines (Wang, 2020). To explore the efficacy and safety of Chinese herbs in the treatment of AOC and its

FIGURE 14
The PPI network of the intersection genes of herb targets and disease targets.
effective targets, we used a method of integrating meta-analysis and network pharmacology analysis.

These meta-analysis results reveal that, compared with chemotherapy alone, the treatment of TCM combined with chemotherapy improved the ORR of AOC patients. In solid tumor treatment, the ORR indicates the sum of patients with complete and partial remission after treatment in relation to the total number of evaluable cases, which is equal to the sum of cases in complete remission and partial remission divided by the total number of evaluable cases. TCM can also improve the 3-year survival rate and PFS, which illustrates its efficacy in increasing the sensitivity of chemotherapy, and avoiding the chemoresistance and experience of relapses in the treatment of AOC. However, TCM had no significant effect on improving the 5-year survival rate in the analysis, although in the original study of Chen (2012), the 5-year survival rate of TCM combined with chemotherapy in the treatment of AOC was 55.6%, while the survival rate of chemotherapy alone was 40.0%, which suggests that integrated TCM and chemotherapy can improve the 5-year survival rate. However, only one study reported this indicator, which may lead to bias, and hence more cases are needed to illustrate this outcome. As for adverse events, our meta-analysis showed that TCM can significantly reduce the incidence of gastrointestinal reactions, including nausea, diarrhea, and constipation caused by chemotherapy, since high frequency herbs, such as Baizhu, Huangqi, and Danshen, function to tonify spleen and stomach, etc. Moreover, one study pointed out that TCM can restore intestinal mucosal epithelial cells, tight junctions, and protect the permeability of the intestinal mucosa barrier in rats (Shi et al., 2017). It therefore has efficacy in reducing gastrointestinal reactions. In addition, TCM has a positive impact in reducing myelosuppression, that is, leukopenia, anemia, and thrombocytopenia. In addition, TCM can reduce the occurrence of liver and kidney damage. TCM has anti-oxidative and anti-inflammatory effects on liver diseases, which may be its mechanism in reducing the occurrence of liver damage (Lam et al., 2016). These potential mechanisms of TCM on renal injury include anti-inflammation, anti-oxidative effect, anti-cell death, and regulation of the energy metabolism by restoring Na⁺-K⁺-ATPase activity etc. (Liu et al., 2021). Due to the limited number of included studies, only some other adverse effects were reduced as a result of treatment with TCM, and more related studies are needed to further verify these. All in all, TCM combined with chemotherapy for AOC patients is safer than chemotherapy alone, and can reduce the incidence of adverse reactions.

After the meta-analysis was completed, we extracted high-frequency herbs from all the TCM prescriptions in the included studies of effective herbs. Their composition was Baizhu, Huangqi, Fuling, Bai Hua She She Cao, Ezhu, Danshen, and Gancao. In TCM theory, OC belongs to “Zhengjia,” the root cause of which is the declining function of the spleen and stomach qi, leading to deficiency of qi and blood. Blood stasis in the ovarian area is another important pathogenesis. The effective herbs of Baizhu, Fuling, Danshen, and Gancao are a Sijunzi decoction, which is good at replenishing qi and invigorating the spleen function. Huangqi is also a qi-invigorating herb that can enhance the efficacy of a Sijunzi decoction, and the above 5 herbs can tonify qi and help the body expel pathogens. The functions of Ezhu are breaking blood and activating qi, removing stagnation, and relieving pain, which is suitable for the pathogenesis of blood stasis. Bai Hua She She Cao is good at clearing away heat and toxic materials as well as reducing swelling and removing stasis, and has been confirmed as a key antitumor herb in many studies. These seven effective herbs are mutually compatible, achieving the effect of strengthening the healthy qi and anti-tumor effect.

We also performed network pharmacology to explore the specific effects of effective herbs on AOC. We screened 120 components and 246 targets of effective herbs and constructed the PPI network by integrating 121 intersecting components and 246 targets of effective herbs and included studies of effective herbs. Their composition was Baizhu, Huangqi, Fuling, Bai Hua She She Cao, Ezhu, Danshen, and Gancao. In TCM theory, OC belongs to “Zhengjia,” the root cause of which is the declining function of the spleen and stomach qi, leading to deficiency of qi and blood. Blood stasis in the ovarian area is another important pathogenesis. The effective herbs of Baizhu, Fuling, Danshen, and Gancao are a Sijunzi decoction, which is good at replenishing qi and invigorating the spleen function. Huangqi is also a qi-invigorating herb that can enhance the efficacy of a Sijunzi decoction, and the above 5 herbs can tonify qi and help the body expel pathogens. The functions of Ezhu are breaking blood and activating qi, removing stagnation, and relieving pain, which is suitable for the pathogenesis of blood stasis. Bai Hua She She Cao is good at clearing away heat and toxic materials as well as reducing swelling and removing stasis, and has been confirmed as a key antitumor herb in many studies. These seven effective herbs are mutually compatible, achieving the effect of strengthening the healthy qi and anti-tumor effect.

We also performed network pharmacology to explore the specific effects of effective herbs on AOC. We screened 120 components and 246 targets of effective herbs and constructed the PPI network by integrating 121 intersecting targets of these seven herbs associated with AOC. Among the herb–component–target network, the 10 most important components were selected according to the degree value, including MOL000098, MOL000422, MOL003896, MOL000392, MOL000354, MOL000296, MOL000449, MOL000006, MOL000378, and MOL000417, including: quercetin, kaempferol, 7-methoxy-2-methyl isoflavone, formononetin, isorhamnetin, hederagenin, stigmastanol, luteolin, 7-O-methylisomucronulatol, and calycosin. Considerable evidence supports the anti-tumor function of the aforementioned components of kaempferol, quercetin,
formononetin, and isorhamnetin (Rauf et al., 2018; Imran et al., 2019; Zhang et al., 2019; Cai et al., 2020).

In addition, the 20 core genes in the PPI networks were TP53, STAT3, JUN, AKT1, MAPK3, RELA, MAPK1, ESR1, IL6, FOS, MAPK14, TNF, CDKN1A, RB1, CCND1, EGF, STAT1, MDM2, MAPK8, and CAV1. Clinical studies have shown that the above core genes are related to the occurrence and development of a variety of tumors. For example, TP53 gets activated in response to a variety of stress signals, such as DNA damage, and hyperproliferative signals, and is involved in the orchestration of basic events that must be overcome for cancer initiation and progression (Bieging et al., 2014). STAT3 cooperates with other targets in promoting glycolysis or lipid catabolism, which have potential roles in different aspects of the metabolism switches in cancer cells that support tumor progression (Martincuks et al., 2020). AKT1 is a direct target of miR-153 in ovarian cancer cells (Li et al., 2017). Next, according to the results of GO enrichment analysis, we found that effective herbs exert a therapeutic effect on AOC mainly through response to reactive oxygen species, response to oxidative stress, and positive regulation of cell migration, which are all closely related to cancer (Prasad et al., 2017; Klaunig, 2018). KEGG enrichment analysis showed that there are many pathways directly related to different types of tumors, such as the pathway in cancer, prostate cancer, bladder cancer, and pancreatic cancer. Other pathways, such as the PI3K/AKT signaling pathway, are also closely associated with the occurrence of cancer (Ma et al., 2020). Hence, the aforementioned pathways play an important role in treating AOC, through which the components of effective herbs may achieve the desired effect.

This review has several limitations. First, the quality evaluation of many articles in terms of allocation concealment and blinding was unclear, and the lack of large, multicenter RCTs may lead to the potential risk of bias and affect the reliability of the results. Second, the differences in application of chemotherapy and duration of treatment among the included trials may lead to a certain degree of heterogeneity. Third, screening of herb components based on DL and OB values may miss some effective components.

Despite these limitations, this study is the first to integrate meta-analysis and network pharmacology to explore the efficacy and potential pharmacological mechanisms of TCM on AOC. We hope it will provide evidence for clinicians to treat AOC patients with a better strategy, as well as provide scientific clues for researchers in this field, which can be further validated experimentally.

Conclusion

In conclusion, this article reveals that combined with chemotherapy, TCM is more effective and safer than chemotherapy alone in treating AOC. In addition, TCM treats AOC patients through a multi-target, multi-component, and multi-pathway mechanism. To make these results more reliable, more rigorously designed RCTs are required in the future and further pharmacological experiments in vivo and in vitro are needed to validate the therapeutic mechanism of these findings.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding authors.

Author contributions

Data curation: ZY, XW, WH, and RY; formal analysis: ZY, XW, SZ, and RY; investigation: ZY, XW, and YX; methodology: ZY, XW, and YY; project administration: ZY, WH, and YY; resources: XW and YX; software: ZY and XW; supervision: ZY; validation: ZY and YX; visualization: ZY, XW, and RY; writing--original draft: ZY, XW, and RY; writing--review and editing: YX and RY. All authors have read and agreed to the published version of the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.1040641/full#supplementary-material

SUPPLEMENTARY FIGURE S1
GO enrichment analysis.

SUPPLEMENTARY FIGURE S2
KEGG enrichment analysis.

SUPPLEMENTARY FIGURE S3
Network of target–pathway.
fetoprotein, HE4 and CA125 levels. *J. Clin. Ration. Drug Use* 8 (07), 102–103. doi:10.15887/j.cnki.13-1389/r.2015.07.062

Yang, L. (2017). Effect of Huoxue Jiedu Decoction on the curative effect and serum inflammatory factors in patients with advanced ovarian cancer. *Med. Inf.* 30 (3), 176–177. <https://doi.org/10.3969/j.issn.1006-1959.2017.03.119>

Yang, L. (2020). Effects of applying TP regimen combined with hyperthermic perfusion chemotherapy on immune function and specific indexes of serum in elderly patients with advanced ovarian cancer. *Nurs. Pract. Res.* 17 (04), 116–117. <https://doi.org/10.3969/j.issn.1672-9676.2020.04.044>

Yang, W., and Mi, X. (2021). Efficacy of compound Daqiqi decoction combined with TC regimen in the treatment of advanced ovarian cancer and its effect on serum B7-H4 and HE4 levels. *Sichuan Tradit. Chin. Med.* 39 (08), 153–156.

Zhang, J. (2016). Efficacy of self-made traditional Chinese medicine decoction on patients with advanced ovarian cancer and its effect on immune function and tumor markers. *Int. Med. Health Rep.* 22 (17), 2691–2694. <https://doi.org/10.3760/cma.j.issn.1007-1245.2016.17.037>

Zhang, C., Zeng, S., and Wang, L. (2018). Influence of integrated traditional Chinese and Western medicine treatment on immunology and other indicators and survival rate of patients with advanced ovarian cancer. *Bright Chin. Med.* 33 (15), 2248–2250. <https://doi.org/10.3969/j.issn.1003-8914.2018.15.046>

Zhang, Y., Chen, C., and Zhang, J. (2019). Effects and significance of formononetin on expression levels of HIF-1α and VEGF in mouse cervical cancer tissue. *Onco. Lett.* 18 (3), 2248–2253. <https://doi.org/10.3892/ol.2019.10567>

Zhao, A., Zhao, S., and Wang, F. (2016). Observation on the curative effect of Taoshong Siwu decoction combined with chemotherapy in the treatment of ovarian cancer. *Med. Inf.* 29 (17), 333–334. <https://doi.org/10.3969/j.issn.1006-1959.2016.17.316>

Zhou, G. (2017). Clinical effect of Jianpi Jiedu Sanjie Recipe combined with TP regimen in the treatment of advanced ovarian cancer. *Traditional Chin. Med. Clin. Res.* 9 (05), 118–119. <https://doi.org/10.3969/j.issn.1674-7860.2017.05.061>

Zhou, Q., Zhou, F., and Zhang, X. (2020). Clinical study of modified Lichong decoction combined with TC regimen in the treatment of advanced ovarian cancer. *New Chin. Med.* 52 (09), 39–43. <https://doi.org/10.13457/j.cnki.jncm.2020.09.011>

Zhu, S., Tan, J., Zhang, C., Wu, Q., Xie, X., and Yin, H. (2016). Effects of Lipsusu combined with nedaplatin chemotherapy on the changes of serum HE4, CA125, CA19-9, AFP, CEA and T cell subsets in patients with advanced ovarian cancer. *J. Hainan Med. Coll.* 22 (15), 1737–1740. <https://doi.org/10.13210/j.cnki.jhmc.20160421.007>